priors.science/reviews/severe-asthma-management

Severe Asthma Management

The current evidence on 16 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

16claims tracked
121primary papers reviewed
5 Jun 2026latest evidence review
Weeklyre-scored against new papers
3 Established · 8 Likely · 5 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableDupilumab reduces exacerbations and improves lung function in type 2-high asthmaDupilumabEstablished90%8
StableAnti-IL-5 agents reduce exacerbations in severe eosinophilic asthmaAnti Il5Established90%8
StableOmalizumab (anti-IgE) reduces exacerbations and healthcare visits in severe allergic asthmaOmalizumabEstablished87%8
StableAnti-IL-5 therapy enables oral corticosteroid dose reduction in corticosteroid-dependent severe eosinophilic asthmaAnti Il5Likely84%8
StableDupilumab enables oral corticosteroid elimination in corticosteroid-dependent severe asthmaDupilumabLikely80%8
StableTezepelumab reduces blood eosinophils, exhaled nitric oxide, and IgE, confirming broad type 2 pathway suppressionTezepelumabLikely80%8
StableTezepelumab reduces exacerbations across type 2-high and type 2-low severe asthmaTezepelumabLikely75%8
StableBlood eosinophils and exhaled nitric oxide fluctuate on inhaled corticosteroids, complicating biologic eligibilityBiomarkersLikely74%8
StableReal-world biologic effectiveness matches trial outcomes with biomarker-based selectionStrategyLikely74%8
StableFractional exhaled nitric oxide identifies type 2 inflammation and predicts response to dupilumab and tezepelumabBiomarkersLikely70%8
StableTotal IgE and allergen sensitisation guide omalizumab eligibility and dosingOmalizumabLikely70%8
StableBlood eosinophil count predicts clinical response to anti-IL-5 therapy in severe asthmaAnti Il5Uncertain63%8
StableBiologic therapy achieves asthma remission in 20-30% of severe asthma patientsStrategyUncertain54%8
StableItepekimab (anti-IL-33) reduces exacerbations in moderate-to-severe asthma without dupilumabTezepelumabUncertain45%8
StableBiologic discontinuation after sustained remission causes loss of asthma control in most patientsStrategyUncertain45%8
StableComposite biomarkers (eosinophils, exhaled nitric oxide, IgE, sensitisation) guide biologic selection in severe asthmaBiomarkersUncertain43%8
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic